|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8299209||RECORDATI RARE||Pharmaceutical composition comprising cyclic somatostatin analogues|| |
(2 years from now)
|US7473761||RECORDATI RARE||Somatostatin analogues|| |
(3 years from now)
Signifor is owned by Recordati Rare.
Signifor contains Pasireotide Diaspartate.
Signifor has a total of 2 drug patents out of which 0 drug patents have expired.
Signifor was authorised for market use on 14 December, 2012.
Signifor is available in solution;subcutaneous dosage forms.
The generics of Signifor are possible to be released after 14 December, 2026.
Market Authorisation Date: 14 December, 2012
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic